Azapirone Explained

Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics.[1] [2] [3] [4] They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).[5] [6] [7] [8] [9] [10]

List of azapirones

The azapirones include the following agents:[11]

Anxiolytics
Antipsychotics
others

Medical uses

Azapirones have shown benefit in general anxiety[12] and augmenting SSRIs in social anxiety[13] and depression.[14] Evidence is not clear for panic disorder[15] and functional gastrointestinal disorders.[16]

Tandospirone has also been used to augment antipsychotics in Japan as it improves cognitive and negative symptoms of schizophrenia.[17] Buspirone is being investigated for this purpose as well.[18] [19]

Side effects

Side effects of azapirones may include dizziness, headaches, restlessness, nausea, and diarrhea.[4] [20]

Azapirones have more tolerable adverse effects than many other available anxiolytics, such as benzodiazepines or SSRIs. Unlike benzodiazepines, azapirones lack abuse potential and are not addictive, do not cause cognitive/memory impairment or sedation, and do not appear to induce appreciable tolerance or physical dependence. However, azapirones are considered less effective with slow onset in controlling symptoms.[21]

Chemistry

Buspirone was originally classified as an azaspirodecanedione, shortened to azapirone or azaspirone due to the fact that its chemical structure contained this moiety, and other drugs with similar structures were labeled as such as well. However, despite all being called azapirones, not all of them actually contain the azapirodecanedione component, and most in fact do not or contain a variation of it. Additionally, many azapirones are also pyrimidinylpiperazines, though again this does not apply to them all.

Drugs classed as azapirones can be identified by their -spirone or -pirone suffix.[22]

Pharmacology

Pharmacodynamics

On a pharmacological level, azapirones varyingly possess activity at the following receptors:[23] [24] [25] [26] [27] [28] [29] [30]

Actions at D4, 5-HT2C, 5-HT7, and sigma receptors have also been shown for some azapirones.[31] [32] [33] [34]

While some of the listed properties such as 5-HT2A and D2 blockade may be useful in certain indications such as in the treatment of schizophrenia (as with perospirone and tiospirone), all of them except 5-HT1A agonism are generally undesirable in anxiolytics and only contribute to side effects. As a result, further development has commenced to bring more selective of anxiolytic agents to the market. An example of this initiative is gepirone, which was recently approved after completing clinical trials in the United States for the treatment of major depression and generalized anxiety disorder. Another example is tandospirone which has been licensed in Japan for the treatment of anxiety and as an augmentation to antidepressants for depression.

5-HT1A receptor partial agonists have demonstrated efficacy against depression in rodent studies and human clinical trials.[35] [36] [37] [38] Unfortunately, however, their efficacy is limited and they are only relatively mild antidepressants. Instead of being used as monotherapy treatments, they are more commonly employed as augmentations to serotonergic antidepressants like the SSRIs.[6] [7] [8] [9] [10] It has been proposed that high intrinsic activity at 5-HT1A postsynaptic receptors is necessary for maximal therapeutic benefits to come to prominence, and as a result, investigation has commenced in azapirones which act as 5-HT1A receptor full agonists such as alnespirone and eptapirone.[39] [40] [41] [42] Indeed, in preclinical studies, eptapirone produces robust antidepressant effects which surpass those of even high doses of imipramine and paroxetine.[39] [40] [41] [42]

Comparison of binding profiles

Affinities of Azapirones for Neurotransmitter Binding Sites (Ki, nM)
Tandospirone
20 ± 3 70 ± 10 7.9 ± 2 27 ± 5
> 100,000 > 100,000 > 100,000 > 100,000
> 100,000 > 100,000 33,000 ± 8,000 > 100,000
1,300 ± 400 3,000 ± 50 6,400 ± 4,000 1,300 ± 200
1,100 ± 200 5,000 ± 700 5,000 ± 1,000 2,600 ± 60
– – – > 100,000
33,000 ± 1,000 > 100,000 15,000 ± 2,000 41,000 ± 10,000
240 ± 50 2,200 ± 200 1,900 ± 200 1,700 ± 300
1,000 ± 400 2,300 ± 300 40 ± 7 1,600 ± 80
6,000 ± 700 1,600 ± 200 1,900 ± 500 1,900 ± 400
8,800 ± 1,000 > 100,000 > 100,000 > 100,000
38,000 ± 5,000 > 100,000 49,000 ± 5,000 > 100,000
> 100,000 > 100,000 > 100,000 > 100,000

Pharmacokinetics

Azapirones are poorly but nonetheless appreciably absorbed and have a rapid onset of action, but have only very short half-lives ranging from 1–3 hours. As a result, they must be administered 2 - 3 times a day. The only exception to this rule is umespirone, which has a very long duration with a single dose lasting as long as 23 hours.[43] Unfortunately, umespirone has not been commercialized. Although never commercially produced, Bristol-Myers Squibb applied for a patent on October 28, 1993, and received the patent on July 11, 1995, for an extended release formulation of buspirone.[44] An extended release formulation of gepirone is currently under development and if approved, should help to improve this issue.

Metabolism of azapirones occurs in the liver and they are excreted in urine and feces. A common metabolite of several azapirones including buspirone, gepirone, ipsapirone, revospirone, and tandospirone is 1-(2-pyrimidinyl)piperazine (1-PP).[45] [46] [47] 1-PP possesses 5-HT1A partial agonist and α2-adrenergic antagonist actions and likely contributes overall mostly to side effects.[45] [46] [48]

Notes and References

  1. Eison AS . Azapirones: history of development . Journal of Clinical Psychopharmacology . 10 . 3 Suppl . 2S–5S . June 1990 . 1973936 . 10.1097/00004714-199006001-00002. 40578767 .
  2. Cadieux RJ . Azapirones: an alternative to benzodiazepines for anxiety . American Family Physician . 53 . 7 . 2349–53 . May 1996 . 8638511 .
  3. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, dos Santos Souza JJ . Azapirones for generalized anxiety disorder . Cochrane Database of Systematic Reviews . 3 . 3. CD006115 . 2006 . 16856115 . Chessick . Cheryl A . 10.1002/14651858.CD006115. 8915394 . etal.
  4. Feighner JP, Boyer WF . Serotonin-1A anxiolytics: an overview . Psychopathology . 22 Suppl 1 . 1. 21–6 . 1989 . 2567039 . 10.1159/000284623.
  5. Book: Pharmacological treatment of social anxiety disorder. 10.1159/000351960. 25225024 . 29 . 2013 . 144–53 . Masdrakis VG, Turic D, Baldwin DS. 978-3-318-02463-0. Anxiety Disorders. Modern Trends in Pharmacopsychiatry.
  6. Van Ameringen M, Mancini C, Wilson C . Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia . Journal of Affective Disorders . 39 . 2 . 115–21 . July 1996 . 8827420 . 10.1016/0165-0327(96)00030-4.
  7. Bouwer C, Stein DJ . Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression . South African Medical Journal . 87 . 4 Suppl . 534–7, 540 . April 1997 . 9180827 .
  8. Dimitriou EC, Dimitriou CE . Buspirone augmentation of antidepressant therapy . Journal of Clinical Psychopharmacology . 18 . 6 . 465–9 . December 1998 . 9864079 . 10.1097/00004714-199812000-00009.
  9. Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH . Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study . The Journal of Clinical Psychiatry . 62 . 6 . 448–52 . June 2001 . 11465522 . 10.4088/JCP.v62n0608.
  10. Yamada K, Yagi G, Kanba S . Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial . Psychiatry and Clinical Neurosciences . 57 . 2 . 183–7 . April 2003 . 12667165 . 10.1046/j.1440-1819.2003.01099.x. free .
  11. Web site: The Use of Common Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances: Alphabetical list of stems together with corresponding INNs . https://web.archive.org/web/20170731013011/http://apps.who.int:80/medicinedocs/en/d/Js4895e/6.html . dead . 2017-07-31 .
  12. Azapirones for generalized anxiety disorder.. Reviews. 10.1002/14651858.CD006115. 16856115 . 3 . 2006 . CD006115 . Chessick CA, Allen MH, Thase M . 2015 . 8915394 . etal.
  13. Book: Pharmacological treatment of social anxiety disorder. Sep 20, 2013 . 10.1159/000351960. 25225024 . 29 . 144–53 . Masdrakis VG, Turic D, Baldwin DS . 978-3-318-02463-0. Anxiety Disorders. Modern Trends in Pharmacopsychiatry.
  14. Serotonergic drugs for depression and beyond. May 1, 2013. Stahl . SM . Lee-Zimmerman . C . Curr Drug Targets. 23531115 . 14 . 5 . 578–85 . 10.2174/1389450111314050007.
  15. Imai. H. Tajika. A. Chen. P. Pompoli. A. Guaiana. G. Castellazzi. M. Bighelli. I. Girlanda. F. Barbui. C. Koesters. M. Cipriani. A. Furukawa. TA. Azapirones versus placebo for panic disorder in adults. The Cochrane Database of Systematic Reviews. Sep 30, 2014. 2014. 9. CD010828. 25268297. 10.1002/14651858.CD010828.pub2. 10590499.
  16. Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. Feb 2013. J Gastroenterol. 10.1007/s00535-012-0726-5. 23254779 . 48 . 2 . 177–81 . 3698430 . Grover M, Camilleri M.
  17. Sumiyoshi T, Matsui M, Nohara S . Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment . The American Journal of Psychiatry . 158 . 10 . 1722–5 . October 2001 . 11579010 . 10.1176/appi.ajp.158.10.1722. etal.
  18. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY . Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study . Schizophrenia Research . 95 . 1–3 . 158–68 . September 2007 . 17628435 . 10.1016/j.schres.2007.06.008 . 36027848 .
  19. Piskulić D, Olver JS, Maruff P, Norman TR . Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist . Human Psychopharmacology . 24 . 6 . 437–46 . August 2009 . 19637398 . 10.1002/hup.1046. 21289248 . free .
  20. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ . Review of the side-effect profile of buspirone . The American Journal of Medicine . 80 . 3B . 17–21 . March 1986 . 2870641 . 10.1016/0002-9343(86)90327-X.
  21. Management of Generalized Anxiety Disorder in Primary Care: Identifying the Challenges and Unmet Needs. 2010. Prim Care Companion J Clin Psychiatry. 10.4088/PCC.09r00772blu. 20694114 . 12 . 2 . 2911006 . Davidson JR, Feltner DE, Dugar A.
  22. Web site: The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances . 2004 . 1 April 2010 . https://web.archive.org/web/20110722013129/http://libdoc.who.int/hq/2004/who_edm_qsm_2004.5.pdf . 2011-07-22 . dead .
  23. 1974152 . 1990 . Hamik . Oksenberg . D . Fischette . C . Peroutka . SJ . Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites . 28 . 2 . 99–109 . Biological Psychiatry . 10.1016/0006-3223(90)90627-E . 25608914 . free .
  24. Barnes NM, Costall B, Domeney AM . The effects of umespirone as a potential anxiolytic and antipsychotic agent . Pharmacology Biochemistry and Behavior . 40 . 1 . 89–96 . September 1991 . 1685786 . 10.1016/0091-3057(91)90326-W. 9762359 . etal.
  25. Ahlenius S, Wijkström A . Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat . European Journal of Pharmacology . 222 . 1 . 69–74 . November 1992 . 1361441 . 10.1016/0014-2999(92)90464-F.
  26. Sumiyoshi T, Suzuki K, Sakamoto H . Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy . Neuropsychopharmacology . 12 . 1 . 57–64 . February 1995 . 7766287 . 10.1016/0893-133X(94)00064-7. etal.
  27. Weiner DM, Burstein ES, Nash N . 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics . The Journal of Pharmacology and Experimental Therapeutics . 299 . 1 . 268–76 . October 2001 . 11561089 . etal.
  28. Hirose A, Kato T, Ohno Y . Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions . Japanese Journal of Pharmacology . 53 . 3 . 321–9 . July 1990 . 1975278 . 10.1254/jjp.53.321. etal. free .
  29. Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M . Binding profile of SM-9018, a novel antipsychotic candidate . Japanese Journal of Pharmacology . 54 . 4 . 478–81 . December 1990 . 1982326 . 10.1254/jjp.54.478. free .
  30. Odagaki Y, Toyoshima R . 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes . Clinical and Experimental Pharmacology & Physiology . 34 . 5–6 . 462–6 . 2007 . 17439416 . 10.1111/j.1440-1681.2007.04595.x . 22450517 .
  31. Bryan Roth . Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY . D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs . Psychopharmacology . 120 . 3 . 365–8 . August 1995 . 8524985 . 10.1007/BF02311185. 13549491 .
  32. Herrick-Davis K, Grinde E, Teitler M . Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors . The Journal of Pharmacology and Experimental Therapeutics . 295 . 1 . 226–32 . October 2000 . 10991983 .
  33. Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D . Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties . Naunyn-Schmiedeberg's Archives of Pharmacology . 376 . 1–2 . 93–105 . October 2007 . 17786406 . 10.1007/s00210-007-0182-6 . 29337002 .
  34. Itzhak Y, Ruhland M, Krähling H . Binding of umespirone to the sigma receptor: evidence for multiple affinity states . Neuropharmacology . 29 . 2 . 181–4 . February 1990 . 1970425 . 10.1016/0028-3908(90)90058-Y. 54326248 . free .
  35. Kennett GA, Dourish CT, Curzon G . Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression . European Journal of Pharmacology . 134 . 3 . 265–74 . February 1987 . 2883013 . 10.1016/0014-2999(87)90357-8.
  36. Blier P, Ward NM . Is there a role for 5-HT1A agonists in the treatment of depression? . Biological Psychiatry . 53 . 3 . 193–203 . February 2003 . 12559651 . 10.1016/S0006-3223(02)01643-8. 23792607 .
  37. Robinson DS, Rickels K, Feighner J . Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression . Journal of Clinical Psychopharmacology . 10 . 3 Suppl . 67S–76S . June 1990 . 2198303 . 10.1097/00004714-199006001-00013. 7849957 . etal.
  38. Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K . Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study . The Journal of Clinical Psychiatry . 69 . 4 . 571–7 . April 2008 . 18373383 . 10.4088/jcp.v69n0408. 39524249 .
  39. Koek W, Patoiseau JF, Assié MB . F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential . The Journal of Pharmacology and Experimental Therapeutics . 287 . 1 . 266–83 . October 1998 . 9765347 . etal.
  40. Koek W, Vacher B, Cosi C . 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential . European Journal of Pharmacology . 420 . 2–3 . 103–12 . May 2001 . 11408031 . 10.1016/S0014-2999(01)01011-1. etal.
  41. Prinssen EP, Colpaert FC, Koek W . 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy . European Journal of Pharmacology . 453 . 2–3 . 217–21 . October 2002 . 12398907 . 10.1016/S0014-2999(02)02430-5.
  42. Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B . High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity . Journal of Medicinal Chemistry . 50 . 20 . 5024–33 . October 2007 . 17803293 . 10.1021/jm070714l.
  43. Holland RL, Wesnes K, Dietrich B . Single dose human pharmacology of umespirone . European Journal of Clinical Pharmacology . 46 . 5 . 461–8 . 1994 . 7957544 . 10.1007/bf00191912. 12117650 .
  44. US . 5431922 . patent . Method for administration of buspirone . 1995-07-11 . 1993-10-23 . Nicklasson AGM . Bristol-Myers Squibb Company url=https://patents.google.com/patent/US5431922 .
  45. Manahan-Vaughan D, Anwyl R, Rowan MJ . The azapirone metabolite 1-(2-pyrimidinyl)piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors . European Journal of Pharmacology . 294 . 2–3 . 617–24 . December 1995 . 8750726 . 10.1016/0014-2999(95)00605-2.
  46. Blier P, Curet O, Chaput Y, de Montigny C . Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission . Neuropharmacology . 30 . 7 . 691–701 . July 1991 . 1681447 . 10.1016/0028-3908(91)90176-C. 44297577 .
  47. Löscher W, Witte U, Fredow G, Traber J, Glaser T . The behavioural responses to 8-OH-DPAT, ipsapirone and the novel 5-HT1A receptor agonist Bay Vq 7813 in the pig . Naunyn-Schmiedeberg's Archives of Pharmacology . 342 . 3 . 271–7 . September 1990 . 2149168 . 10.1007/bf00169437. 24769939 .
  48. Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M . Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats . The Journal of Pharmacology and Experimental Therapeutics . 303 . 3 . 1130–7 . December 2002 . 12438536 . 10.1124/jpet.102.036798 . 14139919 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Azapirone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.